Gliamilide

This classification denotes an anti-diabetic agent with the molecular formula C23H33N5O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OTY52EM5B2, chemically known as 3-pyridinecarboxamide, n-(2-(1-(((((bicyclo(2.2.1)-hept-5-en-2-ylmethyl)amino)carbonyl)amino)sulfonyl)-4-piperidinyl)ethyl)-2-methoxy-, endo but generally known as gliamilide, which bears US NIH Compound Identifier 3037231. European Medicines Agency schedules Gliamilide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07915MIG. The term GLIAMILIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). GLIAMILIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gliamilide under HS 29350090 and SITC 51580. As of Q4 2014, GLIAMILIDE remains the US FDA Preferred Term for this commodity. Gliamilide bears US NLM identifiers UMLS ID C2983990 and NCI Concept Code C91020. SMILES: S(=O)(=O)(N1CCC(CC1)CCNC(=O)C1C(OC)NCCC1)NC(=O)NCC1C2CC(C1)C=C2.